2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - Great Hall AD
Technology and Procedures, Molecular Testing, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Adverse Events, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, MDS, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult
PAPER

718 Upfront transplantation versus pre-transplant cytoreductive therapy in myelodysplastic syndrome or secondary acute myeloid leukemia evolving from myelodysplastic syndrome: A prospective observational cohort study

Qifa Liu, MD, MIN Dai2, Zhongli Hu3, Zhonghui Jiang4, Zhiping Fan5, Fen Huang6, Na Xu, MD7, Hua Jin8, Ling Jiang9, Ren Lin10, Qianwei Liu11, Cuiyan Zhou12, Yigeng Cao II, MD, PhD13, Yiqing Li14, Xiaodan Liu15, Xiaojun Xu16, Ping Zhu17, Can Liu18, Yirong Jiang, MD19, Ruijuan Sun, MD20, Jing Sun, MSc21, Erlie Jiang, MD22, Yu Wang23, Li Xuan24
1 Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China, Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China, Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
2 Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China, Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
3 Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China, Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
4 Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China, Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
5 Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China, Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
6 Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China, Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
7 Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China, Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
8 Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China, Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
9 Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China, Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
10 Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China, Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
11 Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China, Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
12 Department of Hematology, Peking University People’s Hospital, Beijing, China
13 Hematopoietic Stem Cell Transplantation Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China
14 Department of Hematology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
15 Department of Hematology, the Affiliated Hospital of Qingdao University, Qingdao, China
16 Department of Hematology, the Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China
17 Department of Hematology, the First People’s Hospital of Chenzhou, Chenzhou, China
18 Department of Hematology, Hunan Provincial People's Hospital, Changsha, China
19 Department of Hematology, Affiliated Dongguan People's Hospital, Southern Medical University (Dongguan People’s Hospital), Dongguan, China
20 Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China
21 Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China, Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
22 Hematopoietic Stem Cell Transplantation Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China
23 Department of Hematology, Peking University People’s Hospital, Beijing, China
24 Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China, Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China

Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the unique curative therapy for patients with myelodysplastic syndrome (MDS) and secondary AML evolving from MDS (sAML). Currently, whether pre-transplant cytoreductive therapy benefits patients with MDS or sAML undergoing allo-HSCT remains controversial. We aimed to compare the effect of upfront transplantation versus pre-transplant cytoreductive therapy in this population.

Methods: We performed a prospective observational cohort study in eight centers in China. Eligible Patients were aged 14-65 years, had a diagnosis of MDS-refractory anemia with excess blasts (RAEB) or sAML (bone marrow blasts less than 50%), were willing to receive allo-HSCT, had an Eastern Cooperative Oncology Group performance status of 0-2 and hematopoietic cell transplant-comorbidity index of 0-2. Patients were assigned to upfront or cytoreductive group based on patient preferences and the immediate availability of suitable donor. The primary endpoint was 2-year overall survival (OS). This study is registered with ClinicalTrials.gov (NCT02850822) and is complete.

Results: Between January 1, 2018 and June 30, 2022, 1320 patients were enrolled and assigned to upfront (n=660) or cytoreductive (n=660) group. With a median follow-up of 37.4 months (IQR 13.5-52.6), the 2-year OS was 73.5% (95% CI 70.2-76.9) in the upfront group and 57.1% (53.5-61.0) in the cytoreductive group (HR 0.53 [95% CI 0.44-0.64]; P <0.001). The 2-year disease-free survival was 70.3% (95% CI 66.9-73.9) and 51.1% (47.4-55.0; HR 0.52 [95% CI 0.44-0.62]; P<0.001), 2-year cumulative incidence of relaps was 12.4% (95% CI 10.0-15.1) and 22.9% (19.7-26.2; HR 0.51 [95% CI 0.39-0.66]; P<0.001), and 2-year non-relapse mortality was 17.3% (95% CI 14.5-20.3) and 26.0% (22.8-29.5; HR 0.60 [95% CI 0.47-0.75]; P<0.001) in the upfront and cytoreductive groups, respectively. Between enrolment and day 28 after the last dose of study treatment or the start of conditioning, at least one type of grade 3-4 adverse events (AEs) was reported for 241 (36.5%) patients in the upfront group and 562 (85.2%) patients in the cytoreductive group (P<0.001). The most common grade 3-4 AEs in the upfront and cytoreductive groups were infections (109 [16.5%] and 282 [42.7%]), gastrointestinal disorders (49 [7.4%] and 98 [14.8%]), and metabolism and nutrition disorders (41 [6.2%] and 65 [9.8%]). Fourteen (2.1%) patients in the upfront and 92 (13.9%) patients in the cytoreductive group died of AEs (P<0.001). No deaths in the upfront group and 16 deaths in the cytoreductive group were treatment-related.

Conclusions: Upfront transplantation was associated with superior survival, reduced relapse and NRM, and a more favorable safety profile compared with pre-transplant cytoreductive therapy in patients with MDS-RAEB or sAML undergoing allo-HSCT. Upfront transplantation might be a better option for this population.

Qifa Liu, MD: No relevant conflicts of interest to declare.